Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?
by Amy Steele · The Cerbat GemAssembly Biosciences, Inc. (NASDAQ:ASMB – Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $29.48 and traded as high as $29.91. Assembly Biosciences shares last traded at $29.60, with a volume of 81,200 shares.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on ASMB. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st. Mizuho set a $40.00 price target on shares of Assembly Biosciences and gave the company an “outperform” rating in a research report on Thursday, November 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a research note on Monday, December 22nd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Assembly Biosciences has an average rating of “Moderate Buy” and an average price target of $41.75.
Get Our Latest Research Report on Assembly Biosciences
Assembly Biosciences Price Performance
The firm’s fifty day moving average is $28.61 and its two-hundred day moving average is $29.47. The firm has a market capitalization of $447.71 million, a PE ratio of -5.91 and a beta of 1.11.
Institutional Trading of Assembly Biosciences
A number of institutional investors and hedge funds have recently modified their holdings of ASMB. Bank of America Corp DE lifted its holdings in Assembly Biosciences by 6,382.7% during the third quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 3,319 shares during the period. Seven Fleet Capital Management LP purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at $147,000. Acadian Asset Management LLC raised its stake in shares of Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 6,823 shares during the period. Charles Schwab Investment Management Inc. bought a new stake in shares of Assembly Biosciences during the 4th quarter worth $228,000. Finally, Virtus Investment Advisers LLC purchased a new position in shares of Assembly Biosciences in the 4th quarter worth about $251,000. 19.92% of the stock is owned by hedge funds and other institutional investors.
About Assembly Biosciences
Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.
The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.